SCHEMBL20535778

SCHEMBL20535778

C[Si](C)(C)CCOCn1ccc2c(Sc3ccccc3Cl)cccc21

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RHEB Q15382 2/20 0.37
NPC1 O15118 1/20 0.34
EGFR P00533 1/20 0.34
IGF1R P08069 1/20 0.34
SRC P12931 1/20 0.34
FLT4 P35916 1/20 0.34
KDR P35968 1/20 0.34
FLT3 P36888 1/20 0.34
EPHB4 P54760 1/20 0.34
TEK Q02763 1/20 0.34
ATM Q13315 1/20 0.33
HTR6 P50406 1/20 0.31
BACE1 P56817 1/20 0.31
DHFR P00374 1/20 0.30
HPGD P15428 1/20 0.30
KDM4E B2RXH2 1/20 0.30
NPSR1 Q6W5P4 1/20 0.30
RXFP1 Q9HBX9 1/20 0.30
TDP1 Q9NUW8 1/20 0.30
L3MBTL1 Q9Y468 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20535743 0.89 RHEB (0.40) RHEBNPC1EGFRIGF1RSRC
SCHEMBL23709778 0.89 RHEB (0.40) RHEBNPC1EGFRIGF1RSRC
SCHEMBL20535686 0.85 RHEB (0.53) RHEBNPC1EGFRIGF1RSRC
SCHEMBL20535619 0.84 RHEB (0.41) RHEBNPC1EGFRIGF1RSRC
SCHEMBL15091003 0.75 NPC1 (0.39) NPC1EGFRIGF1RSRCFLT4
SCHEMBL16450282 0.75 DGAT1 (0.38) NPC1EGFRIGF1RSRCFLT4
SCHEMBL20535846 0.74 RHEB (0.41) RHEBNPC1RXFP1
SCHEMBL17100403 0.72 POLB (0.38) NPC1EGFRIGF1RSRCFLT4
SCHEMBL1258087 0.72 CDK4 (0.49) NPC1EGFRIGF1RSRCFLT4
SCHEMBL29492554 0.72 CDK4 (0.49) NPC1EGFRIGF1RSRCFLT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11339144-B2 Heteroaryl Rheb inhibitors and uses thereof NAVITOR PHARMACEUTICALS, INC. (US) 2022-05-24 US disclosed
US-11339144-B2 Heteroaryl Rheb inhibitors and uses thereof NAVITOR PHARMACEUTICALS, INC. (US) 2022-05-24 US disclosed
US-20210238165-A1 HETEROARYL RHEB INHIBITORS AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. 2021-08-05 US disclosed
US-20210238165-A1 HETEROARYL RHEB INHIBITORS AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. 2021-08-05 US disclosed
WO-2018191146-A1 HETEROARYL RHEB INHIBITORS AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. (US) 2018-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210238165-A1 HETEROARYL RHEB INHIBITORS AND USES THEREOF RHEB, KRAS, NRAS RHEB 1/4885NPC1 868/4885EGFR 1990/4885
US-11339144-B2 Heteroaryl Rheb inhibitors and uses thereof RHEB, GDI2, KRAS RHEB 1/4885NPC1 403/4885EGFR 2403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.